Michelle Lockley
@mlockley.bsky.social
Medical oncologist and scientist, into all things ovarian cancer. In search of the answer to cancer drug resistance
Reposted by Michelle Lockley
With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...
aacrjournals.org
May 2, 2025 at 12:43 PM
With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
aacrjournals.org/cancerres/ar...
@icr.ac.uk @qmbci.bsky.social
Reposted by Michelle Lockley
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...
Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...
bmjopen.bmj.com
May 2, 2025 at 12:50 PM
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Reposted by Michelle Lockley
📰 Can we use the power of evolution to improve ovarian cancer survival?
A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.
Read more ➡️ www.bci.qmul.ac.uk/general-news...
#AACR25 #medsky #oncosky🧪
A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.
Read more ➡️ www.bci.qmul.ac.uk/general-news...
#AACR25 #medsky #oncosky🧪
Smarter chemotherapy approach could delay drug resistance in ovarian cancer - Barts Cancer Institute - Queen Mary University of London
Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian canc...
www.bci.qmul.ac.uk
April 30, 2025 at 12:10 PM
📰 Can we use the power of evolution to improve ovarian cancer survival?
A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.
Read more ➡️ www.bci.qmul.ac.uk/general-news...
#AACR25 #medsky #oncosky🧪
A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.
Read more ➡️ www.bci.qmul.ac.uk/general-news...
#AACR25 #medsky #oncosky🧪
Can we use the power of evolution to improve ovarian cancer treatment? Our latest paper says yes! Online now at Cancer Research. Thanks to
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.
April 30, 2025 at 1:19 PM
Can we use the power of evolution to improve ovarian cancer treatment? Our latest paper says yes! Online now at Cancer Research. Thanks to
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.
Delighted to speak at Moffitt Cancer centre last week. Great to share our research and really enjoyed the thought provoking discussions. Many thanks to Joel brown for hosting
May 28, 2024 at 8:02 AM
Delighted to speak at Moffitt Cancer centre last week. Great to share our research and really enjoyed the thought provoking discussions. Many thanks to Joel brown for hosting